Ferrous Fumarate Encyclopedia — Scientific Background

What Is Ferrous Fumarate?

Ferrous fumarate (CAS 141-01-5), also known as iron(II) fumarate or iron(2+) fumarate, is the iron(II) salt of fumaric acid. It is chemically characterized by the molecular formula C₄H₂FeO₄ and a relative molecular mass of 169.9. The compound is a fine, reddish orange or reddish brown powder that is odorless and slightly soluble in water. Ferrous fumarate is the iron(II) salt of fumaric acid, occurring as a reddish-orange powder, used to supplement iron intake.

Pharmacopoeial Standards

Ferrous fumarate is monographed in major international pharmacopoeias:

• The International Pharmacopoeia — Ferrous fumarate contains not less than 93.0% and not more than 101.0% of C₄H₂FeO₄, calculated with reference to the dried substance.

• USP — Ferrous Fumarate contains not less than 97.0% and not more than 101.0% of C₄H₂FeO₄, calculated on the dried basis. Ferrous Content: 31.79%–33.20%.

• British Pharmacopoeia (Ph. Eur. monograph 0902) — Used in the prevention and treatment of anaemias. Ferrous Fumarate contains in 200 mg about 65 mg of iron.

The Elemental Iron Advantage

Ferrous fumarate contains approximately 32% elemental iron, the highest among common ferrous salts. This high iron content means that a smaller amount of the compound is required to deliver a therapeutic dose of elemental iron, offering advantages in formulation size and cost efficiency. However, like all ferrous salts, ferrous fumarate is effective in replenishing iron stores but often causes nausea, abdominal discomfort, constipation, or diarrhea.

Mechanisms of Action and Absorption

Conventional Absorption Pathway

The absorption of iron from ferrous fumarate follows the normal physiological pathway for iron. Ferrous iron (Fe²⁺) is absorbed primarily in the duodenum and proximal jejunum through the divalent metal transporter 1 (DMT1). Once inside the enterocyte, iron is either stored as ferritin or transported across the basolateral membrane by ferroportin into the bloodstream, where it binds to transferrin for distribution to tissues.

liposomal Absorption Pathway

Liposomal encapsulation provides a fundamentally different absorption mechanism. The liposomal phospholipid bilayer is similar to that found in human cell membranes. Iron is able to withstand the stomach environment because of liposomal protection, which delays early deterioration and inactivation. This allows liposomal iron to be directly absorbed through the enterocyte's cell membrane via endocytosis, vesicular fusion, and diffusion. Liposomal iron is associated with reduced exposure to gastric contents, decreased interaction with food contents, and no exposure to various digestive juices.

Physiological Functions of Iron

Iron is an essential trace mineral required for numerous physiological processes:

• Hemoglobin Synthesis — Iron is the central atom in the heme group of hemoglobin, enabling oxygen transport from the lungs to tissues

• Oxygen Transport — Iron-containing myoglobin facilitates oxygen storage and transport in muscle tissue

• Electron Transfer — Iron-sulfur clusters and heme groups participate in mitochondrial electron transport chain reactions

• Enzymatic Reactions — Iron is a cofactor for numerous enzymes involved in DNA synthesis, neurotransmitter production, and immune function

• Energy Metabolism — Iron-containing cytochromes are essential for ATP production

The Gastrointestinal Tolerance Challenge

The most significant limitation of conventional ferrous fumarate and other ferrous salts is their gastrointestinal side effect profile. Ferrous salts predictably cause dose-dependent nausea, abdominal pain, and constipation or diarrhea. These adverse effects may lead to poor compliance or early discontinuation.

Recent evidence suggests that alternate-day dosing of ferrous salts may improve tolerability by reducing intestinal iron overload and hepcidin-mediated absorption blockade. Liposomal iron may offer similar or improved efficacy with better tolerability. In pediatric populations, liposomal and sucrosomial preparations—which are essentially tasteless—have shown improved acceptability by the child and a lower incidence of gastrointestinal side effects.

Liposomal ferrous fumarate

Liposomal encapsulation of ferrous fumarate provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the iron molecule, forming a shield that protects it from gastric acid degradation and prevents premature reactions with food components. This delivery system:

• Protects iron from the harsh gastric environment, delaying early deterioration and inactivation

• Enables direct absorption through endocytosis, vesicular fusion, and diffusion

• Reduces gastrointestinal side effects like nausea and constipation

• Enables lower doses due to direct absorption into the bloodstream without the need for protein carriers

Ferrous fumarate nanoliposomes have been successfully produced using the thin film hydration method with cholesterol concentrations of 8, 12, and 16 mg, followed by ultrasonic dispersion and extrusion to reduce particle size. Formulation with higher cholesterol concentration showed better physical characteristics and encapsulation efficiency, with the optimal formulation achieving an encapsulation efficiency of 61.67% ± 0.50.

Clinical Evidence

Pregnancy with Mild Anemia

A prospective, randomized, double-blind trial included 100 pregnant females with mild anemia (Hb 9–11 mg/dL) randomized to either a liposomal iron group or an iron fumarate group. Both groups received oral tablets at 180 mg/day. Hemoglobin at 28–32 weeks was significantly higher in the liposomal iron group (11.18 ± 0.44) than in the ferrous iron group (10.70 ± 0.39). The study concluded that liposomal carriage of iron is linked to targeted delivery of iron and enables lower doses to be administered due to direct absorption into the bloodstream without the need for protein carriers. Clinical research suggests that liposomal iron dramatically raises hemoglobin and ferritin levels in both pregnant women and women with iron insufficiency.

Ongoing Comparative Trials

A prospective, randomized, controlled clinical trial is comparing three oral iron supplementation strategies in adult women with iron-deficiency anemia secondary to abnormal uterine bleeding: daily ferrous salt, ferrous salt administered every other day, or daily liposomal iron, over a total duration of three months. The goal is to compare ferrous salt and liposomal iron for the treatment of iron-deficiency anemia and evaluate how well each treatment is tolerated.

Another multicenter, randomized, open-label, non-inferiority trial is comparing ferrous fumarate 200 mg once daily versus 400 mg on alternate days for 8 weeks in adults with IDA, aiming to evaluate whether alternate-day dosing is non-inferior in terms of hematologic response with fewer adverse effects.

Safety and Regulatory

Ferrous fumarate is generally well tolerated but predictably causes dose-dependent gastrointestinal side effects. The most common side effects are nausea, abdominal discomfort, constipation, or diarrhea. Liposomal encapsulation helps reduce these side effects through targeted delivery and reduced exposure of iron to the gastrointestinal mucosa.

Iron status should be monitored through hemoglobin, ferritin, and transferrin saturation to guide dosing, as even well-tolerated forms should not be supplemented without confirmed deficiency due to the risks of iron overload. Ferrous fumarate is widely commercialized as a dietary supplement ingredient and pharmaceutical agent. It is recommended as a dietary supplement for infants and teenagers. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, Chinese Pharmacopoeia (ChP), GB 1903.12-2015, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

69$/KG